Portola Pharmaceuticals, which is developing a blood thinner and a novel reversal agent for acutely ill patients, raised $122 million in an upsized IPO by offering 8.4 million shares at $14.50, the midpoint of the $13 to $16 range. Portola commands a market cap of $491 million. The company originally set terms for a deal that would have raised $100 million at the midpoint and valued the company at a market cap of $469 million.
